Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Active Rheumatoid Arthritis (Russia)
NCT01231321Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Dec 2007
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Abbott Laboratories. Primary endpoints: Frequency of Adverse Events at 34 weeks, Changes of Physical Examination at 24 weeks and 2 more. Started Dec 2007; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01231321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231321.